StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) stock

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.72+0.06 (+3.61%)

Close on Nov 18, 2026Market cap $4.37MP/E –Yield –

Earnings

Alaunos Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2023
$0
-100.0% on a year earlier
EPS, Q3 FY2023
-$0.04
-$0.04 a year earlier
Latest guidance
Issued
Mar 7, 2023 · 1 item

Quarterly results

Revenue and earnings per share from each of Alaunos Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2024ended Sep 30, 2024Oct 10, 2024before the open–––Filing
Q3 FY2023ended Sep 30, 2023Nov 14, 2023before the open$0-100.0%-$0.04Release
Q2 FY2023ended Jun 30, 2023Aug 14, 2023after the close$4.00K–-$0.04Release
Q1 FY2023ended Mar 31, 2023May 10, 2023before the open––-$0.04Release
Q4 FY2022ended Dec 31, 2022Mar 7, 2023before the open$11.00K–-$0.04Release
Q3 FY2022ended Sep 30, 2022Nov 14, 2022before the open$2.90M–-$0.04Release
Q2 FY2022ended Jun 30, 2022Aug 15, 2022before the open––-$0.05Release
Q1 FY2022ended Mar 31, 2022May 16, 2022before the open––-$0.05Release
Q4 FY2021ended Dec 31, 2021Mar 30, 2022before the open––-$0.05Release
Q1 FY2021ended Jun 30, 2021Aug 9, 2021after the close–––Filing
Q4 FY2020ended Dec 31, 2020Feb 25, 2021after the close–––Filing
Q3 FY2020ended Sep 30, 2020Nov 5, 2020after the close–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Alaunos Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
operating outflows, excluding debt service costsFY2023$35.00M – $40.00M–NewMar 7, 2023

Guidance history

Every forecast Alaunos Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 7, 2023operating outflows, excluding debt service costsFY2023$35.00M – $40.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Alaunos Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. News
  4. News
  5. News
  6. News
  7. News
  8. News
  9. Results
  10. Results
  11. Results
  12. Results
  13. Update
  14. Update
  15. News

See a number that looks wrong?